MetrioPharm AG is developing a new class of drugs for early-intervention treatment and long-term control of chronic inflammation towards the goal of reversing and preventing diseases of aging.

Inflammation is a root cause of the decline in health and chronic degenerative diseases.
Controlling chronic inflammation holds great promise for extending prime health into very old age for the majority of people.

Our drug candidates have shown the potential to be significantly safer and more tolerable than existing therapies. MetrioPharm’s lead compound MP1032 is currently in Phase II clinical testing.

MetrioPharm is headquartered in Zurich and operates a research facility in Berlin.